Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by H. Spierings, E. L.
Right arrow Articles by Saxena, P. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by H. Spierings, E. L.
Right arrow Articles by Saxena, P. R.
NEUROLOGY 1980;30:696
© 1980 American Academy of Neurology

Antimigraine drugs and cranial arteriovenous shunting in the cat

Egilius L. H. Spierings, M.D. and Pramod R. Saxena, M.D.

Department of Pharmacology, Faculty of Medicine, Erasmus University, Rotterdam, the Netherlands.

The effects of three antimigraine drugs—ergotamine, dihydroergotamine, and methysergid—mn the distribution of flow throughout the cephalic circulation of the cat were studied, using microspheres of a suitable size to separate capillary flow from flow through the arteriovenous anastomoses. Ergotamine and dihydroergotamine significantly decreased the fraction of carotid blood flow shunted through the arteriovenous anastomoses, a mode of action that reemphasizes the need for further clinical studies on the involvement of arteriovenous anastomoses in the pathophysiology of migraine headaches.

Address correspondence and reprint requests to Dr. Spierings, Department of Pharmacology, Erasmus University, P.O. Box 1738, Rotterdam, the Netherlands.

Accepted for publication October 15, 1979.

Part of the ergotamine data was presented at the twenty-first annual meeting of the American Association for the Study of Headache, Boston, June 1979.




This article has been cited by other articles:


Home page
 CephalalgiaHome page
T Wienecke, J. Hansen, J Petersen, K. Olsen, M Ashina, and P Tfelt-Hansen
Sumatriptan Does Not Affect Arteriovenous Oxygen Differences in Jugular and Cubital Veins in Normal Human Subjects
Cephalalgia, October 1, 2008; 28(10): 1081 - 1085.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
K.M.A. Welch
Drug Therapy of Migraine
N. Engl. J. Med., November 11, 1993; 329(20): 1476 - 1483.
[Full Text]

Home page
 CephalalgiaHome page
P. R Saxena and M. D Ferrari
From Serotonin Receptor Classification to the Antimigraine Drug Sumatriptan
Cephalalgia, August 1, 1992; 12(4): 187 - 196.
[Abstract] [PDF]

Home page
 ANGIOLOGYHome page
M. I. Weintraub
Methysergide (Sansert) Treatment in Acute Stroke Community Pilot Study
Angiology, March 1, 1985; 36(3): 137 - 142.
[Abstract] [PDF]

Home page
 CephalalgiaHome page
P. R. Saxena, N. A. Koedam, J. Heiligers, and R. P. Hof
Ergotamine-Induced Constriction of Cranial Arteriovenous Anastomoses in Dogs Pretreated with Phentolamine and Pizotifen
Cephalalgia, June 1, 1983; 3(2): 71 - 81.
[Abstract] [PDF]